Author Correction: Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis

Juan Carlos O. Velez , George Therapondos and Luis A. Juncos

Nature Reviews Nephrology (2019) <https://doi.org/10.1038/s41581-019-0218-4> Published online 13 November 2019

In Table 2 of the original article published online, the response rates achieved with terlipressin and noradrenaline as described by reference 197 were incorrectly stated to be 70% and 83%, whereas they should have been 83% and 70%. In addition, a footnote has now been added to Table 2 to indicate studies that included patients with HRS-2. Finally, the overall reversal rates achieved with terlipressin based on studies outside the USA, which were described in the original article to range from ~40–70%, have been corrected to ~40–80%. These corrections have been made to the HTML and PDF versions of the manuscript.

<https://doi.org/10.1038/s41581-020-0255-z> | Published online 27 January 2020

© Springer Nature Limited 2020